Related Experiment Video
Updated: Jun 4, 2025

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat
Jessica Huston1, Dontia Orey2, Ashish Kumar3
1Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, 580 W. 8th Street, Jacksonville, FL, USA.
Abstract:
Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.
Related Concept Videos
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Pharmacokinetics: Overview
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Biopharmaceutics and Pharmacokinetics: Overview

